AstraZeneca PLC
NYSE:AZNDrug Manufacturers - General
-$3.04 today
- Market cap
- $277.23B
- Beta
- 0.21
- P/E (TTM)
- 25.7
- EPS (TTM)
- $6.75
- Dividend yield
- 1.80%
Volume 2.54M
Average 1.96M
AZN Debt Repayment
Cash used to repay borrowings during the period.
AstraZeneca PLCNYSE: AZN
Debt Repayment · Q3 FY2026 · quarter ended Sep 2026
Debt repayment turns positive
Q3 FY2026 debt repayment was $2.08B, compared with -$387.65M a year earlier. Trailing-twelve-month debt repayment was $793.27M. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Debt repayment amounted to 2.8% of revenue in FY2025, down 0.5 pp from a year earlier.
- Debt repayment increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly debt repayment holds near $2.08B or moves back toward the trailing-twelve-month quarterly average of $198.32M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (1.65B) USD
- Year-over-year change
- -191.2%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.65B) | -191.2% |
| FY2024 | 2024-12-31 | 1.81B | +287.5% |
| FY2023 | 2023-12-31 | (965M) | +19.4% |
| FY2022 | 2022-12-31 | (1.2B) | -115.2% |
| FY2021 | 2021-12-31 | 7.89B | — |
Debt Repayment vs competitors
How AZN compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +8.5% is the 8th highest of 10, against a peer median of +121.9%.
- Debt repayment amounts to 1.3% of revenue for AZN, versus a peer median of 11.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 36.44B DKK | -8.0% | — | 11.1% | |
| LTM Jun 2026 | $18.64B USD | +723.0% | — | 28.1% | |
| LTM Jun 2026 | $16.59B USD | +704.5% | — | 29.8% | |
| LTM Jun 2026 | $15.22B USD | +47.0% | — | 19.1% | |
| LTM Jun 2026 | $6.49B USD | +98.1% | -0.9% | 13.2% | |
| LTM Jun 2026 | $1.78B USD | +121.9% | -72.4% | 2.8% | |
| LTM Jun 2026 | $1.32B USD | +157.5% | — | 3.5% | |
| LTM Sep 2026 | $793.27M USD | +8.5% | +11.3% | 1.3% | |
| LTM Sep 2026 | $787M USD | -108.7% | +8.9% | 0.8% | |
| LTM Jun 2026 | $418M USD | +130.0% | -70.3% | 0.6% | |
| Peer median (excluding AZN) | — | +121.9% | -35.6% | 11.1% | |
Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (265M) | 2.5B | 6.9B | 8.69B | 10.23B |
| Depreciation & Amortization | 4.1B | 5.25B | 4.93B | 5.07B | 5.73B |
| Deferred Income Tax | (615M) | (619M) | 0 | 0 | 0 |
| Stock-Based Compensation | 615M | 619M | 579M | 0 | 0 |
| Change in Working Capital | 2.02B | 3.76B | 300M | (893M) | (1.16B) |
| Accounts Receivables | (961M) | (1.35B) | (1.43B) | (1.62B) | 0 |
| Inventory | 1.58B | 3.94B | (669M) | (131M) | 0 |
| Accounts Payables | 961M | 1.35B | 1.43B | 0 | 0 |
| Other Working Capital | 444M | (184M) | 969M | 862M | (1.16B) |
| Other Non-Cash Items | 105M | (1.7B) | (2.37B) | (1B) | (220.71M) |
| Operating Cash Flow | 5.96B | 9.81B | 10.35B | 11.86B | 14.58B |
| Capital Expenditures | (2.2B) | (2.57B) | (3.78B) | (4.59B) | (5.91B) |
| Acquisitions (Net) | (9.43B) | (1.06B) | (1.18B) | (3.93B) | (1.24B) |
| Purchases of Investments | (184M) | (159M) | (136M) | (96M) | (229M) |
| Sales of Investments | 105M | 42M | 129M | 108M | 131M |
| Other Investing Activities | 654M | 789M | (1.52B) | (2.14B) | (2.66B) |
| Investing Cash Flow | (11.06B) | (2.96B) | (4.06B) | (7.98B) | (6.81B) |
| Debt Repayment | 7.89B | (1.2B) | (965M) | 1.81B | (1.65B) |
| Common Stock Issued | 29M | 29M | 33M | (43M) | (481M) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (3.86B) | (4.36B) | (4.48B) | (4.63B) | (4.97B) |
| Other Financing Activities | (418M) | (1.29B) | (1.15B) | (1.13B) | (442M) |
| Financing Cash Flow | 3.65B | (6.82B) | (6.57B) | (4B) | (7.54B) |
| Effect of Forex Changes | (62M) | (80M) | (60M) | (93M) | 46M |
| Net Change in Cash | (1.51B) | (55M) | (346M) | (208M) | 269M |
| Free Cash Flow | 3.76B | 7.24B | 6.57B | 7.28B | 8.67B |
AstraZeneca PLC
NYSE:AZN
Intrinsic Alpha fair value
Locked
Current Price
$178.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.